RTA Certificate under regulation 74(5) of SEBI DP Regulations for quarter ended December 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parmax Pharma has submitted a routine compliance certificate to BSE confirming that all share certificates received for dematerialization during the quarter ended December 31, 2025 were properly processed by its Registrar and Share Transfer Agent, Purva Sharegistry (India) Pvt. Ltd. The certificate confirms that securities were mutilated and cancelled after verification, and the depository's name was substituted as the registered owner within SEBI-prescribed timelines. Only one shareholder (Rameshbhai Savjibhai Patel) dematerialized 2,500 shares during the quarter. The certificate was signed by Managing Director Dr. Umang Gosalia on January 12, 2026.
This is a standard quarterly regulatory filing required under SEBI rules and carries no material impact on the company's financials or stock price. It simply confirms routine administrative compliance of share dematerialization activity.